Study was never initiated due to company decision. No study subjects were ever enrolled or treated.

This study will investigate the safety and efficacy of Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution in patients with glaucoma or ocular hypertension who have elevated IOP on dorzolamide hydrochloride/timolol maleate combination therapy.

Inclusion Criteria:

• Diagnosis of ocular hypertension or glaucoma in each eye
• Requires IOP-lowering treatment in both eyes

Exclusion Criteria:

• Use of dorzolamide or carbonic anhydrase within 4 weeks
• Any other active ocular disease other than ocular hypertension or glaucoma (eg, uveitis, ocular infections or severe dry eye)
• Required chronic use of ocular medications other than study medication during the study (intermittent use of certain products eg, artificial tears are permitted)
• Use of oral, injectable or topical ophthalmic steroids within 21 days
• Any eye laser surgery within 3 months
• Any intraocular surgery (eg cataract surgery) within 6 months